Sunshine Act Meeting of the Uniform Formulary Beneficiary Advisory Panel, 46040 [07-4028]

Download as PDF 46040 Federal Register / Vol. 72, No. 158 / Thursday, August 16, 2007 / Notices Military Health Care, a duly established subcommittee of the Defense Health Board. DATE OF MEETING: September 5, 2007. TIME OF MEETING: 9 a.m. to 3 p.m. PLACE OF MEETING: National Transportation Safety Board Conference Center, 429 L’Enfant Plaza, Washington, DC 20594. PURPOSE OF MEETING: To obtain, review, and evaluate information related to the Task force’s congressionally directed mission to examine matters relating to the future of military health care. The Task Force members will receive briefings on topics related to the delivery of military health care during the public meeting. AGENDA: Discussion topic will be Command and Control of the Military Health Care System. Prior to the public meeting the Task Force will conduct a Preparatory Work Meeting from 8 a.m.–8:50 a.m. to solely analyze relevant issues and facts in preparation for the Task Force’s next public meeting. In addition, the Task Force, following its public meeting, will conduct an additional Preparatory Work Meeting from 3:10 p.m. to 4 p.m. to analyze relevant issues and facts in preparation for the Task Force’s next public meeting. Both Preparatory Meetings will be held at the National Transportation Safety Board Conference Center, and pursuant to 41 Code of Federal Regulations, Part 102–3.160(a). Both Preparatory Work Meetings are closed to the public. Additional information and meeting registration is available online at the Task Force Web site: www.DoDfuturehealthcare.net. FOR FURTHER INFORMATION CONTACT: Colonel Christine Bader, Executive Secretary, Department of Defense Task Force on the Future of Military Health Care, TMA/Code: DHS, Five Skyline Place, Suite 810, 5111 Leesburg Pike, Falls Church, Virginia 22041–3206, (703) 681–3279, ext. 109 (christine.bader@ha.osd.mil). Open sessions of the meeting will be limited by space accomodations. Any interested person may attend; however, seating is limited to the space available at the National Transportation Safety Board Conference Center. Individuals or organizations wishing to submit written comments for consideration by the Task Force should provide their comments in an electronic (PDF Format) document through the Task Force Web site (https:// DoDfuturehealthcare.net) at the ‘‘Contact Us’’ page, no later than five (5) rwilkins on PROD1PC63 with NOTICES SUPPLEMENTARY INFORMATION: VerDate Aug<31>2005 17:27 Aug 15, 2007 Jkt 211001 business days prior to the scheduled meeting. Dated: August 13, 2007. L.M. Bynum, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 07–4027 Filed 8–14–07; 10:27 am] BILLING CODE 5001–06–M DEPARTMENT OF DEFENSE Office of the Secretary Sunshine Act Meeting of the Uniform Formulary Beneficiary Advisory Panel Department of Defense, Assistant Secretary of Defense (Health Affairs). ACTION: Notice of meeting. AGENCY: SUMMARY: Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended) and the Sunshine in the Government Act of 1976 (U.S.C. 552b, as amended) the Department of Defense announces the following Federal Advisory Committee Meeting: NAME OF COMMITTEE: Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel). DATE OF MEETING: Tuesday, September 18, 2007. LOCATION: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004. TIME: 8 a.m. to 4 p.m. PURPOSE OF MEETING: The Panel will review and comment on recommendations made to the Director, TRICARE Management Activity, by the Pharmacy and Therapeutics (P&T) Committee regarding the Uniform Formulary. MEETING AGENDA: Sign-In; Welcome and Opening Remarks; Opportunity for Public Citizen Comments; Scheduled Therapeutic Class Review— (Leukotriene Modifying Agents (LMAs), Growth Stimulating Agents (GSAs), Second Generation (newer) Antihistamines (SGAs) and Designated newly Approved Drugs; Panel discussions, vote, and comments following each therapeutic class review. MEETING ACCESSIBILITY: Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102–3.140 through 102–3.165, and the availability of space this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing in. All persons must sign in legibly. WRITTEN STATEMENTS: Pursuant to 41 CFR 102–3.105(j) and 102–3.140, the public or interested organizations may PO 00000 Frm 00009 Fmt 4703 Sfmt 4703 submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel’s Designated Federal Officer. The Designated Federal Officer’s contact information can be obtained from the GSA’s FACA Database—https:// www.fido.gov/facadatabase/public.asp. Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting then these statements must be submitted no later than five (5) business days prior to the meeting in question. The Designated Federal Officer will review all submitted written statements and provide copies to all the committee members. PUBLIC COMMENTS: In addition to written statements, the Panel will set aside one (1) hour for individual or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice. Additionally, they will be afforded the opportunity to address the Panel. Registration for addressing the Panel in on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than five (5) minutes to present their comments, and at the end of the one (1) hour time period no further public comments will be accepted. FOR FURTHER INFORMATION CONTACT: Major Travis Watson, Designated Federal Officer, Uniform Formulary Beneficiary Advisory Panel, Skyline 5, Suite 810–5111 Leesburg Pike, Falls Church, Virginia 22041–3206, Telephone: (703) 681–2890—Fax: (703) 681–1940, E-mail Address: baprequests@tma.osd.mil. Dated: August 13, 2007. L.M. Bynum, Alternate OSD Federal Register Liaison Officer. [FR Doc. 07–4028 Filed 8–14–07; 10:27 am] BILLING CODE 5001–06–M DEPARTMENT OF DEFENSE Office of the Secretary [DoD–2007–OS–0088] Privacy Act of 1974; Systems of Records Defense Finance and Accounting Service, DOD. ACTION: Notice to add a system of records. AGENCY: E:\FR\FM\16AUN1.SGM 16AUN1

Agencies

[Federal Register Volume 72, Number 158 (Thursday, August 16, 2007)]
[Notices]
[Page 46040]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-4028]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Sunshine Act Meeting of the Uniform Formulary Beneficiary 
Advisory Panel

AGENCY: Department of Defense, Assistant Secretary of Defense (Health 
Affairs).

ACTION:  Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C., Appendix, as amended) and the Sunshine in the 
Government Act of 1976 (U.S.C. 552b, as amended) the Department of 
Defense announces the following Federal Advisory Committee Meeting:

Name of Committee: Uniform Formulary Beneficiary Advisory Panel 
(hereafter referred to as the Panel).

Date of Meeting: Tuesday, September 18, 2007.

Location: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., 
Washington, DC 20004.

Time: 8 a.m. to 4 p.m.

Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director, TRICARE Management Activity, by 
the Pharmacy and Therapeutics (P&T) Committee regarding the Uniform 
Formulary.

Meeting Agenda: Sign-In; Welcome and Opening Remarks; Opportunity for 
Public Citizen Comments; Scheduled Therapeutic Class Review--
(Leukotriene Modifying Agents (LMAs), Growth Stimulating Agents (GSAs), 
Second Generation (newer) Antihistamines (SGAs) and Designated newly 
Approved Drugs; Panel discussions, vote, and comments following each 
therapeutic class review.

Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 
CFR 102-3.140 through 102-3.165, and the availability of space this 
meeting is open to the public. Seating is limited and will be provided 
only to the first 220 people signing in. All persons must sign in 
legibly.

Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, the 
public or interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer. The Designated Federal Officer's 
contact information can be obtained from the GSA's FACA Database--
https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting then 
these statements must be submitted no later than five (5) business days 
prior to the meeting in question. The Designated Federal Officer will 
review all submitted written statements and provide copies to all the 
committee members.

Public Comments: In addition to written statements, the Panel will set 
aside one (1) hour for individual or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice. Additionally, they will be afforded the opportunity to address 
the Panel. Registration for addressing the Panel in on a first-come, 
first-serve basis. Those wishing to address the Panel will be given no 
more than five (5) minutes to present their comments, and at the end of 
the one (1) hour time period no further public comments will be 
accepted.

FOR FURTHER INFORMATION CONTACT: Major Travis Watson, Designated 
Federal Officer, Uniform Formulary Beneficiary Advisory Panel, Skyline 
5, Suite 810-5111 Leesburg Pike, Falls Church, Virginia 22041-3206, 
Telephone: (703) 681-2890--Fax: (703) 681-1940, E-mail Address: 
baprequests@tma.osd.mil.

    Dated: August 13, 2007.
L.M. Bynum,
Alternate OSD Federal Register Liaison Officer.
[FR Doc. 07-4028 Filed 8-14-07; 10:27 am]
BILLING CODE 5001-06-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.